paroxysmal nocturnal hemoglobinuria (PNH) | Page 8 | Aplastic Anemia & MDS International Foundation Return to top.

paroxysmal nocturnal hemoglobinuria (PNH)

Aplastic Anemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms: The 8th (Virtual) Patient Conference, June 26, 2021


8th Seattle Patient Conference: Ask an Expert
 H. Joachim Deeg, MD

8th Seattle Patient Conference - Living Well with MDS/MPN
 Krisstina Gowin, DO, University of Arizona

Event Date: 
Sat, 06/26/2021 - 8:00am (EDT)
Conference Event Type: 

Spring Patient and Family Virtual Conference, April 10, 2021

Event Date: 
Sat, 04/10/2021 - 8:00am (EDT)
Conference Event Type: 

Iptacopan (LNP023)

Iptacopan (LNP023) is a first-in-class, orally administered, potent and highly selective factor B inhibitor of the alternative complement pathway. It is currently in clinical development for treating PNH.

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH)


If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.

Find Out More:

Find Out More:


BCX9930 is an oral small molecule inhibitor of Factor D currently in Phase 1 clinical development for the treatment of complement-mediated diseases.

Find Out More:

Share with